Subscribe X
Back to Top

Learn

June 17, 2018 by Marc De Hert, MD, PhD, & Johan Detraux, MPsy | JAMA Psychiatry

The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication

(JAMA Psychiatry) – Over the last 2 decades, there has been increasing widespread use of second-generation antipsychotic (SGA) medications in nonpsychotic pediatric populations in the United States and Europe. As the ubiquity of SGA drugs in treatment plans for these children and adolescents grows, so does the controversy surrounding them.

Antipsychotic medications can induce cardiometabolic abnormalities (such as obesity, hyperglycemia, and dyslipidemia) that are associated with an increased risk of cardiovascular disease and type 2 diabetes mellitus (DM). These adverse effects tend to appear faster and to a greater extent in children and adolescents than in adults. In this vulnerable population, roughly the same hierarchy for risk of weight gain with these agents has been identified (with olanzapine having the highest risk, risperidone showing an intermediate risk, and aripiprazole having less effect on body weight) but at a higher rate. Generally, this weight gain is rapid during the first few weeks or months of medication use, slows gradually thereafter, and often reaches a plateau within 1 year. Although the occurrence of new cases of DM in antipsychotic-exposed youths remains small, SGA-treated children nevertheless have a 2-fold to 3-fold increased risk of developing type 2 DM compared with SGA-naive children. This risk increases with higher cumulative doses (particularly with olanzapine), longer treatment duration, and adjunctive antidepressant use, and it seems to remain high for a certain period of time after discontinuation. High interindividual variability of these adverse effects among patients treated with a given agent suggests that underlying biological or genetic factors predispose children to metabolic adverse effects during SGA treatment. This explains why not all children and adolescents show these adverse effects.

Source: JAMAnetwork.com/journals/jamapsychiatry/fullarticle/2683877

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Related Blogs

  • Dr. David Healy

    Dr. David Healy

    Dr. Healy is a professor of psychiatry at Cardiff University in Wales and an author on the history of pharmaceuticals and government regulation.
    READ BLOG
  • Mad In America: Robert Whitaker

    Mad In America: Robert Whitaker

    Journalist and author Bob Whitaker distills the latest in pharmaceutical and mental health research.
    READ BLOG
  • Selling Sickness

    Selling Sickness

    Creating a new partnership movement to challenge the selling of sickness.
    READ BLOG
  • Kathy Brous

    Kathy Brous

    A serial of Kathy's recovery journey as an adult with attachment disorder.
    READ BLOG
  • Nev Jones

    Nev Jones

    Exploring the intersections of psychiatry, philosophy, neuroscience, cultural theory, critical community psychology and the mad/user/survivor movement.
    READ BLOG
  • 1boringoldman

    1boringoldman

    Retired psychiatrist and raconteur offers insightful analysis of the day's events from the woods of Georgia.
    READ BLOG